Last update 30 Aug 2026

CV-0801(GlaxoSmithKline)

Overview

Basic Info

Drug Type
Prophylactic vaccine, mRNA vaccine
Synonyms
CV-0801
Target-
Action
stimulants
Mechanism
Immunostimulants
Therapeutic Areas
Infectious DiseasesRespiratory Diseases
Active Indication-
Inactive Indication
COVID-19
Originator Organization
GSK PlcGSK Plc
Active Organization-
Inactive Organization
CureVac NVGSK PlcGSK Plc
License Organization-
Drug Highest PhasePendingPhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with CV-0801(GlaxoSmithKline)
NCT05960097
/ CompletedPhase 2
A Phase 2 Randomized, Active-controlled, Observer-blind Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Booster Dose of Investigational COVID-19 mRNA Vaccines in Healthy Adults Who Previously Received a Complete Primary Vaccination Series With or Without Booster Dose(s)
100 Clinical Results associated with CV-0801(GlaxoSmithKline)
Login to view more data
100 Translational Medicine associated with CV-0801(GlaxoSmithKline)
Login to view more data
100 Patents (Medical) associated with CV-0801(GlaxoSmithKline)
Login to view more data
100 Deals associated with CV-0801(GlaxoSmithKline)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 2
United States
CureVac NV
01 Aug 2023
COVID-19Phase 2
United States
GSK PlcGSK Plc
01 Aug 2023
COVID-19Phase 2
Australia
CureVac NV
01 Aug 2023
COVID-19Phase 2
Australia
GSK PlcGSK Plc
01 Aug 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT05960097 (CTgov)
Phase 2
COVID-19
692
CV0701 mRNA COVID-19 Vaccine
(Part A: CV0701 mRNA COVID-19 Vaccine (Low Dose))
kbvkfjtuxw(bhvsujzzgr) = rylqvtpmcw ucpovqqsav (qydgebuucg, zmndhxhotz - ldstwgotwe)
View more
-
23 Oct 2025
CV0701 mRNA COVID-19 Vaccine
(Part A: CV0701 mRNA COVID-19 Vaccine (Medium Dose))
kbvkfjtuxw(bhvsujzzgr) = cgqwfhtbxo ucpovqqsav (qydgebuucg, eabkfcuvwj - ivlsuhiipw)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free